AEGIS-II trial shows CSL112 formulation did not significantly reduce cardiovascular events in acute MI patients, but may benefit those with higher baseline LDL levels.
The AEGIS-II trial found that four weekly infusions of a novel human apolipoprotein A-I formulation, CSL112, did not significantly reduce the primary endpoint of cardiovascular death, MI, or stroke in patients with acute MI and additional risk factors. However, a subgroup analysis revealed potential benefits in patients with higher baseline LDL levels. The full AEGIS-II results have sparked debate on the future of the HDL-raising hypothesis.
April 06, 2024
5 Articles